Review
2024 September
Volume : 12 Issue : 3


From pathophysiology to personalized care: A comprehensive review of diabetic kidney disease

Tereda A

Pdf Page Numbers :- 246-252

Abiy Tereda1,*, MD

 

1Georgetown American Univerisity, 4618 Millcove drive, USA

 

*Corresponding author: Abiy Tereda, MD, Georgetown American Univerisity, 4618 Millcove drive, USA. Email: abiykifle@hotmail.com

 

Received 2 April 2024; Revised 4 June 2024; Accepted 10 June 2024; Published 18 June 2024

 

Citation: Tereda A. From pathophysiology to personalized care: A comprehensive review of diabetic kidney disease. J Med Sci Res. 2024; 12(3):246-252. DOI: http://dx.doi.org/10.17727/JMSR.2024/12-46

 

Copyright: © 2024 Tereda A et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

View Full Text | PDF

Abstract

Diabetic kidney disease (DKD) stands as a prevalent and significant complication in individuals with type 2 diabetes, impacting nearly half of this population. It holds the primary position as the cause of chronic kidney disease and end-stage kidney disease globally, associated with heightened cardiovascular morbidity and mortality. Despite the array of available interventions to prevent and manage DKD, such as regulating blood sugar levels, controlling blood pressure, and inhibiting the renin-angiotensin system, numerous patients continue to grapple with the ongoing decline in kidney function and unfavorable outcomes. This comprehensive review offers an updated exploration of the pathophysiology, diagnosis, prevention, and treatment of DKD. Special attention is devoted to emerging treatment modalities displaying promising outcomes in clinical trials, notably sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, non-steroidal mineralocorticoid receptor antagonists, and innovative agents addressing inflammation and fibrosis. The discourse also delves into the complexities and opportunities associated with integrating these therapies into clinical practice, emphasizing the necessity for personalized and all-encompassing care for DKD patients. The conclusion outlines future directions, urging further research and providing recommendations to advance both understanding and practical approaches in this domain.

 

Keywords: pathophysiology; personalized care; diabetic kidney disease

Subscription